Search

everythinglearnresearchcommunity

for

Search:↓

User seeks availability of Breezula and its delayed trials. Asks for success with similar topical antiandrogens like fluridil.

The user has experienced limited hair regrowth using 1mg oral finasteride, topical minoxidil foam, and occasional dermarolling since August 2023. They are considering switching to dutasteride, adding oral minoxidil 2.5 mg, and RU58841 to improve results.

A 21-year-old male shares progress pictures showing improvement in hair growth using daily topical minoxidil 5%, microneedling 1.25mm, and 500mg of saw palmetto. He reports new and healthy hair growth, indicating success in managing androgenic alopecia.

Finasteride, minoxidil, and derma rolling are currently the best treatments for hair loss. New treatments like TDM-105795, GT20029, PP405, HMI 115, Tsuji, Scube 3, RU, JW0061, Topilutamide, and verteporfin show promise but have uncertain timelines.

The conversation is about the availability of a 2% Pyrilutamide treatment by Kintor for hair loss. A user confirms that it is not available.

Joe Rogan mentioned Batana Oil for hair loss, but many believe the video is fake and created using AI. Most users are skeptical of his endorsement, comparing it to his previous controversial recommendations like Ivermectin for COVID.

The conversation is about adding a low dose of pyrilutamide to a hair loss treatment regimen. Specific treatments mentioned include Minoxidil, finasteride, and RU58841.

Jordan-Iliad has been using a combination of finasteride, minoxidil, stemoxydine, microneedling, saw palmetto, peppermint and jojoba oils, ketoconazole shampoo, and Purador shampoo/conditioner for 3 months to treat their hair loss with stunning results. They have also recently started taking oral minoxidil 1.25mg/day in hopes of achieving even better results over the next 3 months.

PP405 and ABS-201 are promising treatments for male pattern baldness. PP405 shows rapid hair growth in human trials, while ABS-201 shows significant regrowth in animal studies but is still in early human trials.

User seeks participants for Verteporfin group buy. Verteporfin, FDA approved, may regenerate hair follicles and sweat glands through heavy microneedling.

Hair loss theory involves 3alpha-hydroxysteroid reductase (3AHD) converting DHT to androstenol. Discussion explores potential treatments and encourages more research.

The user is using a comprehensive hair loss treatment including oral dutasteride, minoxidil (both oral and topical), topical finasteride, RU58841, ketoconazole shampoo, and a derma roller, while also using anabolic steroids. Opinions vary, with some users noting stability or slight improvement, while others suggest the treatment may not be effective due to anabolic use.

The conversation is about the effectiveness and trustworthiness of Pyrilutamide hair loss treatment sold by Hairlisciously, with concerns about product purity and a request for alternative suppliers. No specific treatments were confirmed to be used by participants.

The conversation is about when GT20029, a hair loss treatment, might be available on the grey market, with users discussing the challenges of compounding it and speculating it might be available after phase 2 results, similar to pyri. Specific treatments mentioned are pyri, RU58841, and GT20029.

Taurine shows potential in combating hair loss caused by chemical stress, especially when combined with other treatments like finasteride. Finasteride demonstrated better stress-reducing effects in the study.

Pelage Pharmaceuticals raised $120M for their hair loss treatment, PP405, showing strong investor confidence despite limited data. There is skepticism about its efficacy and long-term effects compared to treatments like GT20029.

The conversation discusses the effects of Pyrilutamide on hair growth after two months, with one person noting that while new hair regrowth isn't apparent, existing hair appears longer and thicker.

Clascoterone 5% shows potential for hair thickening and darkening, especially when combined with treatments like finasteride. It may be a good alternative for those who experience side effects from other treatments.

After a year on dutasteride and oral minoxidil, the user experienced significant hair regrowth, improving from Norwood 2 to almost Norwood 1. They added RU58841, microneedling, rosemary oil, GHK-Cu, and annurca apple supplement to their regimen and are now noticing hair loss in the temple area.

Chime Biologics and Hope Medicine are speeding up the launch of a first-in-class antibody drug, HMI-115, for endometriosis and androgenic alopecia. The treatment involves a series of subcutaneous injections, has shown promising results in phase 1, and continues to promote hair regrowth even after the treatment is stopped.

The conversation is about using finasteride and KX826 for hair loss treatment. The original poster is using 0.25 mg of finasteride every other day due to side effects at a higher dose.

Injectable GHK-CU and BPC157 were discussed for hair loss, but users did not notice significant hair changes. BPC157 was noted to help with shoulder issues.

RU58841 was the only treatment that slowed hair loss and reduced irritation for a DUPA sufferer after trying finasteride, minoxidil, and dutasteride with no success. The user continues using 6mg oral minoxidil, 0.5mg dutasteride, and an 8% RU58841 solution.

A new hair loss treatment involving Keratin Microsphere Gel is discussed, with skepticism and jokes about its effectiveness and comparisons to other treatments. Users are doubtful and make light of the situation, referencing past disappointments and the study's focus on mice.

The discussion is about a hair loss drug called pyrilutamide. Users discuss its efficacy, safety, and expected market release around 2025-2026, with some expressing concerns about the authenticity of current market offerings.

Recruitment for a verteporfin trial and a separate hair cloning trial using verteporfin and other methods is underway, with locations in Jordan, NYC, Beverly Hills, and Memphis. Dr. Bloxham is conducting the hair cloning trial, and interested participants are encouraged to contact him directly.

The user has been treating hair loss for a year using Hims topical finasteride/minoxidil, derma stamping, and RU58841, with plans to continue and hopes for more significant results. They have noticed some small hair growth at the temples and will provide updates on their progress.

Pyrilutamide and RU58841 are androgen receptor antagonists that block receptors without significantly reducing testosterone or DHT levels. Any indirect effect on androgen levels is likely negligible.

The conversation discusses aggressive hair loss treatments, including finasteride, dutasteride, minoxidil, topical cetirizine, and experimental options like Estrogel, oh-flutamide, and RU58841. Users share experiences and suggest trying oral minoxidil and el cranell, noting the complexity and challenges of treating hair loss.

A user is advocating for Phase 3 trials of the hair loss treatment PP405 to be conducted in Germany, citing benefits like a diverse patient base and faster access for European patients. Despite skepticism about the petition's influence, the user believes it can demonstrate significant interest and potentially influence strategic decisions.